Alemtuzumab under scrutiny because of risk of stroke in some patients with MS on: April 26, 2019, 07:15:37 am #1 The Lancet (April 27, 2019) contains an article on this topic though there is no easy access to it. However, another article (from Lancet Neurology, February 15) (see link below) explains the situation under discussion:QuoteReports of stroke in patients having taken alemtuzumab for multiple sclerosis prompt a safety review by the European Medicines Agency.The February 15 article, "Intracerebral hemorrhage during alemtuzumab administration":https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(19)30076-6/fulltext Logged MS Speaks--online for 20 yearsSPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010. Glatopa (glatiramer acetate 40mg 3 times/week) 12/16/20 - 3/16/24.
